Development and validation of risk prediction models for cardiovascular events in black adults: The Jackson heart study cohort

JAMA Cardiology

Volumn 1, Issue 1, 2016, Pages 15-25

  Fox, Ervin R ^a   Samdarshi, Tandaw E ^a   Musani, Solomon K ^a   Pencina, Michael J ^b   Sung, Jung Hye ^c   Bertoni, Alain G ^d   Xanthakis, Vanessa ^e   Balfour, Pelbreton C ^d   Shreenivas, Satya S ^f   Covington, Carolyn ^g   Liebson, Philip R ^h   Sarpong, Daniel F ⁱ   Butler, Kenneth R ^a   Mosley, Thomas H ^a   Rosamond, Wayne D ^j   Folsom, Aaron R ^k   Herrington, David M ^d   Vasan, Ramachandran S ^e   Taylor, Herman A ^l  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c JACKSON STATE UNIVERSITY   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^g HOWARD UNIVERSITY   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

ⁱ XAVIER UNIVERSITY OF LOUISIANA   (United States)

^j IL   (United States)

^k UNIVERSITY OF MINNESOTA   (United States)

^l MOREHOUSE SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; ENDOTHELIN; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROCORTISONE; INSULIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ALGORITHM; ANGINA PECTORIS; ANKLE BRACHIAL INDEX; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLACK PERSON; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; ESTIMATED GLOMERULAR FILTRATION RATE; ETHNICITY; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INCIDENCE; INSULIN BLOOD LEVEL; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MISSISSIPPI; OUTCOME ASSESSMENT; PREDICTION; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; SMOKING; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; VALIDATION PROCESS; FORECASTING; GENETICS; MIDDLE AGED; REPRODUCIBILITY; THEORETICAL MODEL;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; FORECASTING; HUMANS; MIDDLE AGED; MISSISSIPPI; MODELS, THEORETICAL; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT;

EID: 84995908158     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2015.0300     Document Type: Article

References (50)

1. Roger VL, Go AS, Lloyd-Jones DM, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2012 update: a report from the American Heart Association [published correction appears in Circulation. 2012; 125(22):e1002]. Circulation. 2012; 125(1):e2-e220. doi:10.1161/CIR.0b013e31823ac046.
2. Bahrami H, Kronmal R, Bluemke DA, et al. Differences in the incidence of congestive heart failure by ethnicity: the Multi-Ethnic Study of Atherosclerosis. Arch Intern Med. 2008; 168(19): 2138-2145.
3. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol. 2008; 101(7):1016-1022.
4. Lumley T, Kronmal RA, Cushman M, Manolio TA, Goldstein S. A stroke prediction score in the elderly: validation and Web-based application. J Clin Epidemiol. 2002; 55(2):129-136.
5. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991; 22(3):312-318.
6. Koller MT, Leening MJ, Wolbers M, et al. Development and validation of a coronary risk prediction model for older U.S. and European persons in the Cardiovascular Health Study and the Rotterdam Study. Ann Intern Med. 2012; 157(6):389-397.
7. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97(18):1837-1847.
8. Chambless LE, Folsom AR, Sharrett AR, et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J Clin Epidemiol. 2003; 56(9):880-890.
9. Chambless LE, Heiss G, Shahar E, Earp MJ, Toole J. Prediction of ischemic stroke risk in the Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2004; 160(3):259-269.
10. Agarwal SK, Chambless LE, Ballantyne CM, et al. Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) study. Circ Heart Fail. 2012; 5(4):422-429.
11. Pencina MJ, D'Agostino RB Sr, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation. 2009; 119(24):3078-3084.
12. Chiuve SE, Cook NR, Shay CM, et al. Lifestyle-based prediction model for the prevention of CVD: the Healthy Heart Score. J Am Heart Assoc. 2014; 3(6):e000954. doi:10.1161/JAHA.114.000954.
13. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2014; 129(25, suppl 2):S74-S75]. Circulation. 2014; 129(25)(suppl 2):S49-S73.
14. Taylor HA Jr, Wilson JG, Jones DW, et al. Toward resolution of cardiovascular health disparities in African Americans: design and methods of the Jackson Heart Study. Ethn Dis. 2005; 15(4)(suppl 6): S6-4-17.
15. Fuqua SR, Wyatt SB, Andrew ME, et al. Recruiting African-American research participation in the Jackson Heart Study: methods, response rates, and sample description. Ethn Dis. 2005; 15(4) (suppl 6):S6-18-29.
16. Matsushita K, Selvin E, Bash LD, Astor BC, Coresh J. Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis. 2010; 55(4):648-659.
17. Kim HC, Greenland P, Rossouw JE, et al. Multimarker prediction of coronary heart disease risk: the Women's Health Initiative. J Am Coll Cardiol. 2010; 55(19):2080-2091.
18. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009; 302(1):49-57.
19. Velagaleti RS, Gona P, Larson MG, et al. Multimarker approach for the prediction of heart failure incidence in the community. Circulation. 2010; 122(17):1700-1706.
20. Orchard TJ, Strandness DE Jr. Assessment of peripheral vascular disease in diabetes: report and recommendations of an international workshop sponsored by the American Diabetes Association and the American Heart Association September 18-20, 1992 New Orleans, Louisiana. Circulation. 1993; 88(2):819-828.
21. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986; 57(6):450-458.
22. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995; 25(5):1056-1062.
23. Ingelsson E, Sullivan LM, Murabito JM, et al. Prevalence and prognostic impact of subclinical cardiovascular disease in individuals with the metabolic syndrome and diabetes. Diabetes. 2007; 56(6):1718-1726.
24. Keku E, Rosamond W, Taylor HA Jr, et al. Cardiovascular disease event classification in the Jackson Heart Study: methods and procedures. Ethn Dis. 2005; 15(4)(suppl 6):S6-62-70.
25. Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015; 162(1):W1-73.
26. Cox DR. Regression Models and Life-Tables: Breakthroughs in Statistics. New York, NY: Springer; 1992:527-541.
27. Shtatland ES, Kleinman K, Cain EM. Model Building in PROC PHREG With Automatic Variable Selection and Information Criteria. Philadelphia, PA: SAS Users Group International Paper; 2005:206-230.
28. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982; 247(18):2543-2546.
29. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008; 27(2): 157-172.
30. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008; 117(6):743-753.
31. Wang TJ. Multiple biomarkers for predicting cardiovascular events: lessons learned. J Am Coll Cardiol. 2010; 55(19):2092-2095.
32. Pepe MS. Problems with risk reclassification methods for evaluating prediction models. Am J Epidemiol. 2011; 173(11):1327-1335.
33. Demler OV, Paynter NP, Cook NR. Tests of calibration and goodness-of-fit in the survival setting. Stat Med. 2015; 34(10):1659-1680.
34. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006; 355(25):2631-2639.
35. Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL Jr. Biology of the natriuretic peptides. Am J Cardiol. 2008; 101(3A):3-8.
36. Woodard GE, Rosado JA. Natriuretic peptides in vascular physiology and pathology. Int Rev Cell Mol Biol. 2008; 268:59-93.
37. Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J. 2013; 34(12):886-893c.
38. Lafontan M, Moro C, Sengenes C, Galitzky J, Crampes F, Berlan M. An unsuspected metabolic role for atrial natriuretic peptides: the control of lipolysis, lipid mobilization, and systemic nonesterified fatty acids levels in humans. Arterioscler Thromb Vasc Biol. 2005; 25(10):2032-2042.
39. You H, Laychock SG. Atrial natriuretic peptide promotes pancreatic islet β-cell growth and Akt/Foxo1a/cyclin D2 signaling. Endocrinology. 2009; 150(12):5455-5465.
40. Olsen MH, Hansen TW, Christensen MK, et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension. 2005; 46(4):660-666.
41. Musani SK, Vasan RS, Bidulescu A, et al. Aldosterone, C-reactive protein, and plasma B-type natriuretic peptide are associated with the development of metabolic syndrome and longitudinal changes in metabolic syndrome components: findings from the Jackson Heart Study. Diabetes Care. 2013; 36(10):3084-3092.
42. Frohlich ED. State of the Art Lecture: risk mechanisms in hypertensive heart disease. Hypertension. 1999; 34(4, pt 2):782-789.
43. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001; 286(11): 1317-1324.
44. Fox ER, Taylor HA Jr, Benjamin EJ, et al. Left ventricular mass indexed to height and prevalent MRI cerebrovascular disease in an African American cohort: the Atherosclerotic Risk in Communities study. Stroke. 2005; 36(3):546-550.
45. Taylor HA, Penman AD, Han H, et al. Left ventricular architecture and survival in African-Americans free of coronary heart disease (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol. 2007; 99(10):1413-1420.
46. Blecker S, Matsushita K, Fox E, et al. Left ventricular dysfunction as a risk factor for cardiovascular and noncardiovascular hospitalizations in African Americans. Am Heart J. 2010; 160(3):488-495.
47. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 2000; 102(4):470-479.
48. Bikkina M, Larson MG, Levy D. Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy. J Am Coll Cardiol. 1993; 22(4):1111-1116.
49. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 1998; 32(5):1454-1459.
50. Butler J, Kalogeropoulos A, Georgiopoulou V, et al.; Health ABC Study. Incident heart failure prediction in the elderly: the Health ABC Heart Failure Score. Circ Heart Fail. 2008; 1(2):125-133.